FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new therapeutic method; it can be used in medicine. The invention discloses a method for the treatment of malignant neoplasm expressing NK-1 receptor, using a composition containing CAR-T-cells and NK-1 receptor-binding ligand (NK1RL) conjugate with fluorescein isothiocyanate (FITC) as active therapeutic agents.
EFFECT: obtainment of methods and compositions for CAR-T-cell therapy.
40 cl, 19 dwg, 1 tbl, 19 ex
| Title |
Year |
Author |
Number |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
2013 |
- Kloss Kristofer K.
- Sadlejn Mishel
|
RU2729401C2 |
| ENHANCER OF T-CELLS OR B-CELLS WITH MEMORY FUNCTION, INHIBITOR OF CANCER RECURRENCE AND INDUCER FOR INDUCING MEMORY FUNCTION IN T-CELLS OR B-CELLS |
2018 |
- Tamada Koji
- Sakoda Yukimi
- Adachi Keishi
- Nakamura Takafumi
|
RU2802824C2 |
| POLY-LIGAND MEDICINAL CONJUGATES AND USE THEREOF |
2016 |
- Huang, Baohua Robert
- Dai, Jian
- Wang, Zhongbo
- Xie, Xueyuan
- Liu, Xiaodong
- Hu, Xinli
|
RU2722449C2 |
| PEPTIDE OF A MALIGNANT TUMOUR, CONSTITUTING A TARGET |
2017 |
- Fukuda, Michiko
- Nonaka, Motohiro
|
RU2770197C2 |
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST |
2019 |
- Go, William Y.
- Woolfson, Adrian
|
RU2788524C2 |
| METHODS FOR MODULATING CART-CELLS |
2017 |
|
RU2774232C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES |
2019 |
|
RU2824391C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF |
2020 |
- Yang Yang
- Xu Jianyan
- Tao Weikang
|
RU2826119C1 |
| SELECTIVE INHIBITOR OF EGFR HAVING MUTATION IN EXON 18 AND/OR EXON 21 |
2018 |
- Abe, Naomi
- Hasako, Shinichi
|
RU2785657C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE |
2019 |
- Sadelain, Michel
- Mansilla-Soto, Jorge, A.
- Eyquem, Justin
- Dobrin, Anton
|
RU2812917C2 |
